tert-butyl 2-methyl-4-methylenepiperidine-1-carboxylate | 203661-75-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: tert-butyl 2-methyl-4-methylenepiperidine-1-carboxylate
• 英文别名: 1-(tert-butoxycarbonyl)-2-methyl-4-methylenepiperidine；tert-butyl 2-methyl-4-methylidenepiperidine-1-carboxylate
• CAS: 203661-75-0
• 化学式: C₁₂H₂₁NO₂
• 分子量: 211.304
• InChiKey: MWKRDIXJPNEIPH-UHFFFAOYSA-N

物化性质

• 沸点：
  269.3±29.0 °C(Predicted)
• 密度：
  0.98±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  29.5
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  tert-butyl 2-methyl-4-methylenepiperidine-1-carboxylate 生成 7-(tert-Butoxycarbonyl)-6-methyl-7-azaspiro[3.5]nonan-2-one
  参考文献：
  名称：

  Benzopiperidine derivatives

  摘要：

  本茨哌啶衍生物，由公式(I)表示，其盐或水合物，其制备方法以及包含其的药物: 其中变量如说明书中所述。这些化合物作为药物有效，用于预防和治疗这些各种炎症性疾病和免疫性疾病，如类风湿性关节炎、特应性皮炎、银屑病、哮喘和伴随器官移植的排斥反应。

  公开号：

  US06518423B1
• 作为产物：
  描述：

  硫酸二甲酯 、 N-Boc-4-亚甲基哌啶 在 四甲基乙二胺 、 仲丁基锂 作用下， 以 乙醚 、 正己烷 为溶剂， 反应 6.0h， 以75%的产率得到tert-butyl 2-methyl-4-methylenepiperidine-1-carboxylate
  参考文献：
  名称：

  WO2008/108957

  摘要：

  公开号：

文献信息

• Modular access to substituted cyclohexanes with kinetic stereocontrol
  作者：Yangyang Li、Yuqiang Li、Hongjin Shi、Hong Wei、Haoyang Li、Ignacio Funes-Ardoiz、Guoyin Yin

  DOI：10.1126/science.abn9124

  日期：2022.5.13

  biologically active compounds. Although methods for the synthesis of thermodynamically favored, disubstituted cyclohexanes are well established, a reliable and modular protocol for the synthesis of their stereoisomers is still elusive. Herein, we report a general strategy for the modular synthesis of disubstituted cyclohexanes with excellent kinetic stereocontrol from readily accessible substituted methylenecyclohexanes

  取代的六元环烃是生物活性化合物的常见成分。尽管合成热力学有利的二取代环己烷的方法已经很成熟，但合成其立体异构体的可靠和模块化方案仍然难以捉摸。在此，我们报告了通过实施链行走催化从易于获得的取代亚甲基环己烷模块化合成具有优异动力学立体控制的二取代环己烷的一般策略。从机制上讲，最初引入与环己烷相邻的空间要求高的硼酯基团是指导立体化学结果的关键。
• BENZOPIPERIDINE DERIVATIVES
  申请人：Eisai Co., Ltd.

  公开号：EP0934941A1

  公开（公告）日：1999-08-11

  This invention provides a benzopiperidine derivative represented by the following general formula (I), its salt or hydrates thereof:    wherein R1 to R3 may be the same or different and each represents hydrogen, optionally substituted lower alkyl, optionally substituted lower cycloalkyl or the like, provided that the case where R1 to R3 each represents methyl in the case of lower alkyl is excluded; R represents hydrogen, lower alkyl or the like; E represents N, C or the like; Z represents O, S, SO, SO2 or the like; and the ring G represents an optionally substituted heteroaryl ring having one or more nitrogen atoms. Those are effectively used for a drug for preventing or remedying inflammatory immunologic diseases and autoimmune diseases, or a drug for preventing or remedying rheumatism, collagen disease, asthma, nephritis, ischemic reflow disorders, psoriasis, atopic dermatitis or rejection reaction accompanying organ transplantation.

  本发明提供了由以下通式(I)代表的苯并哌啶衍生物、其盐或水合物： 其中 R1 至 R3 可以相同或不同，各自代表氢、任选取代的低级烷基、任选取代的低级环烷基或类似物，但不包括 R1 至 R3 在低级烷基中各自代表甲基的情况；R 代表氢、低级烷基或类似物；E 代表 N、C 或类似物；Z 代表 O、S、SO、SO2 或类似物；环 G 代表具有一个或多个氮原子的任选取代的杂芳基环。这些药物可有效用于预防或治疗炎症性免疫疾病和自身免疫疾病，或用于预防或治疗风湿病、胶原病、哮喘、肾炎、缺血性回流障碍、牛皮癣、特应性皮炎或器官移植时的排斥反应。
• NOVEL NON-IMIDAZOLE COMPOUNDS
  申请人：Aslanian Robert G.

  公开号：US20080119487A1

  公开（公告）日：2008-05-22

  Disclosed are novel compounds of the formula Also disclosed are pharmaceutical compositions comprising the compounds of Formula I. Also disclosed are methods of treating various diseases or conditions, such as, for example, allergy, allergy-induced airway responses, and congestion (e.g., nasal congestion) using the compounds of Formula I. Also disclosed are methods of treating various diseases or conditions, such as, for example, allergy, allergy-induced airway responses, and congestion (e.g., nasal congestion) using the compounds of Formula I in combination with a H 1 receptor antagonist.
• PIPERIDINYL-PIPERIDINE AND PIPERAZINYL-PIPERIDINE FOR USE IN THE TREATMENT OF DIABETES OR PAIN
  申请人：Aslanian Robert G.

  公开号：US20100093692A1

  公开（公告）日：2010-04-15

  The present invention relates to Compounds of Formula (I), compositions comprising the compounds, and methods of using the compounds to treat or prevent pain, diabetes, a diabetic complication, impaired glucose tolerance (IGT) or impaired fasting glucose (IFG) in a patient.
• US6518423B1
  申请人：——

  公开号：US6518423B1

  公开（公告）日：2003-02-11